Cost-Effectiveness of Vibrant System vs. Linaclotide in Chronic Idiopathic Constipation.

ABSTRACT:

Introduction

Chronic idiopathic constipation (CIC) is a common disorder that has a large unmet clinical need, affecting 8.0-12.0% of the US population and disproportionately affecting female individuals more than male individuals. Patients and physicians are equally dissatisfied with over-the-counter and prescription treatments. Physician dissatisfaction is at 78%. CIC has a significant negative impact on quality of life (QoL). The objective of this analysis was to compare the total cost and QoL of the Vibrant System vs. linaclotide, over 1-3 years of treatment.

Methods

Markov models were utilized to project 1-3-year US costs and health outcomes (quality adjusted life years, QALYs) comparing the Vibrant System to the current standard of care pharmacologic therapy (linaclotid

SUBMITTER: Voigt JD 

PROVIDER: S-EPMC11782372 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature